Citius Oncology (CTOR) Net Cash Flow (2023 - 2026)

Citius Oncology's Net Cash Flow history runs 4 years deep, the most recent figure standing at -$4.7 million for Q1 2026.

• In Q1 2026, Net Cash Flow changed N/A year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$1.3 million (down 3807.81% YoY), while the FY2025 annual figure was $3.9 million, up 3504182.14% from the prior year.
• Net Cash Flow was -$4.7 million for Q1 2026 at Citius Oncology, down from $3.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $3.4 million in Q4 2025 to a low of -$4.7 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$265209.4 across 4 years, with a median of -$100256.0 in 2023.
• Biggest YoY gain for Net Cash Flow was 100.35% in 2024; the steepest drop was 67.02% in 2024.
• A 4-year view of Net Cash Flow shows it stood at -$262652.0 in 2023, then soared by 87.41% to -$33069.0 in 2024, then jumped by 10292.46% to $3.4 million in 2025, then plunged by 238.34% to -$4.7 million in 2026.
• The last three Net Cash Flow figures came in at -$4.7 million (Q1 2026), $3.4 million (Q4 2025), and -$33069.0 (Q2 2024), per Business Quant data.